H146
4-羟基美芬妥英
≥98% (HPLC)
别名:
(±)-5-乙基-5-(4-羟苯基)-3-甲基海因, (±)-5-乙基-5-(4-羟苯基)-3-甲基羟基香豆素-2,4-二酮
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C12H14N2O3
化学文摘社编号:
分子量:
234.25
NACRES:
NA.22
PubChem Substance ID:
UNSPSC Code:
12352100
MDL number:
Assay:
≥98% (HPLC)
InChI
1S/C12H14N2O3/c1-3-12(8-4-6-9(15)7-5-8)10(16)14(2)11(17)13-12/h4-7,15H,3H2,1-2H3,(H,13,17)
SMILES string
CCC1(NC(=O)N(C)C1=O)c2ccc(O)cc2
InChI key
OQPLORUDZLXXPD-UHFFFAOYSA-N
assay
≥98% (HPLC)
solubility
DMSO: >5 mg/mL
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
美芬妥英的 YP2C19 代谢物。
Application
药理活性研究：
用于电子捕获气相色谱法的分析物
- 药物对代谢的影响
- 体外微粒体细胞色素P450活性
用于电子捕获气相色谱法的分析物
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
J Caslavska et al.
Journal of chromatography. B, Biomedical applications, 656(1), 219-231 (1994-06-03)
Phenotypes for hydroxylation can be predicted by using mephenytoin and dextromethorphan as substrates, whereas phenotypes for acetylation can be determined with caffeine as probe drug. After single-dose administration of one of these drugs, of two of them simultaneously, or of
Xunge Zhang et al.
Pharmaceutical biology, 58(1), 247-252 (2020-04-01)
Context: Cepharanthine (CEP) extracted from the roots of Stephania cepharantha Hayata (Menispermaceae), has a range of therapeutic potential in clinical conditions. Whether it affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear.Materials and methods: The effects of
Xiao-Ping Chen et al.
Clinical pharmacology and therapeutics, 73(3), 264-271 (2003-03-07)
This study was designed to define the effect of low-dose aspirin administration on the activity of cytochrome P450 (CYP) in normal human subjects. Aspirin, 50 mg daily, was given for 14 days to 18 nonsmoking healthy male volunteers. A modified
M. Salsali, et al.,
Journal of Pharmacological and Toxicological Methods, 44, 461-465 (2001)
Sonja Krösser et al.
European journal of clinical pharmacology, 62(4), 277-284 (2006-03-10)
The 5HT(1A) receptor agonist sarizotan is in clinical development for the treatment of dyskinesia, a potentially disabling complication in Parkinson's disease. We investigated the effect of sarizotan on the clinical pharmacokinetics of probe drugs for cytochrome P450 (CYP) to evaluate
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持